Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

Regina García-Delgado, Dunia de Miguel, Alicia Bailén, José Ramón González, Joan Bargay, José F. Falantes, Rafael Andreu, Fernando Ramos, Mar Tormo, Salut Brunet, Antonio Figueredo, Javier Casaño, Ángeles Medina, Llorenç Badiella, Antonio Fernández Jurado, Guillermo Sanz

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

40 Cites (Scopus)

Resum

We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules. © 2014 The Authors.
Idioma originalEnglish
Pàgines (de-a)744-750
RevistaLeukemia Research
Volum38
Número7
DOIs
Estat de la publicacióPublicada - 1 de gen. 2014

Fingerprint

Navegar pels temes de recerca de 'Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia'. Junts formen un fingerprint únic.

Com citar-ho